Trial Profile
A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Simtuzumab (Primary)
- Indications Hepatic fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 18 Dec 2021 This trial has been completed in Italy global end of the trial is 2017-01-03 , according to European Clinical Trials Database record.
- 18 Oct 2021 Results of a pooled analysis (NCT01672879 and NCT03053063 studies) assessing the associations between histologic and noninvasive tests of fibrosis (NITs) with liver-related complications in patients with NASH cirrhosis published in the Hepatology
- 08 Dec 2020 Results of an analysis (n=2154) assessing associations between histologic and non-invasive fibrosis tests with clinical and patient-reported outcomes from four clinical studies: NCT01672866, NCT01672879, NCT03053050 and NCT03053063 published in the Gastroenterology